Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK1 | P23458 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5230371 | 0.91 | GPR119 (0.38) | JAK2JAK1GPR119P2RX3ALDH1A1 | |
| SCHEMBL5246757 | 0.90 | CNR1 (0.39) | MEN1KMT2ANPC1GAA | |
| SCHEMBL5246764 | 0.90 | CNR1 (0.39) | MEN1KMT2ANPC1GAA | |
| SCHEMBL5246761 | 0.90 | CNR1 (0.39) | MEN1KMT2ANPC1GAA | |
| SCHEMBL5229997 | 0.89 | STS (0.43) | KDM4EJAK2JAK1GPR119P2RX3 | |
| SCHEMBL5230017 | 0.89 | STS (0.43) | KDM4EJAK2JAK1GPR119P2RX3 | |
| SCHEMBL5230008 | 0.89 | STS (0.43) | KDM4EJAK2JAK1GPR119P2RX3 | |
| SCHEMBL16490799 | 0.88 | MEN1 (0.47) | LMNAMEN1KMT2AGPR119ALDH1A1 | |
| SCHEMBL6414267 | 0.86 | CYP11B2 (0.36) | LMNAKMT2ARAB9AGPR119P2RX3 | |
| SCHEMBL5230373 | 0.86 | GPR119 (0.41) | KMT2AJAK2JAK1GPR119P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170197961-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | RAQUALIA PHARMA INC. (JP) | 2017-07-13 | — | — | US | disclosed |
| US-7622487-B2 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20060167052-A1 | Piperidine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1000085-B1 | TREATMENT OF INSULIN RESISTANCE WITH GROWTH HORMONE SECRETAGOGUES | PFIZER PROD INC (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1553084-A1 | PIPERIDINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Pharmaceutical Company Limited (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-6867202-B1 | Increasing level of endogenous growth hormone using growth hormone secretagogue such as 2-amino-N-(2-(3a-benzyl-2-methy-3-oxo-2,3,3a,4,6,7-hexahydro-pyrazolo-(4,3 -c)pyridin-5-yl)-1-benzyloxymethyl-2-oxo-ethyl)-isobutyramide tartarate salt | PFIZER INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-6630487-B2 | Treatment of insulin resistance with growth hormone secretagogues | PFIZER INC. | 2003-10-07 | — | — | US | disclosed |
| US-20030100561-A1 | Administering 2-amino-N-(1-(3a-benzyl-2-methyl-3-oxo-2,3,3a, 4,6,7-hexahydro-pyrazolo(4,3-c)pyridine-5-carbonyl)-4-phenyl-butyl) -isobutyramide for treating congestive heart failure, obesity | CARPINO PHILIP ALBERT (US) | 2003-05-29 | — | — | US | disclosed |
| US-6448263-B1 | SYNTHESIS ROUTES FOR SUCH AS 2-AMINO-N-(2-(3A-(R)-BENZYL-2-METHYL-3-OXO-2,3,3A,4,6,7-HEXAHYDRO-PYRAZOLO -(4,3-C) PYRIDIN-5-YL)-1-(R)-BENZYLOXYMETHYL-2-OXO-ETHYL)-ISOBUTYRAMIDE L-TARTARIC ACID SALT | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167052-A1 | Piperidine derivative, process for producing the same, and use | OPRL1, OXTR, OPRM1 | LMNA 2745/4885MEN1 3581/4885KMT2A 642/4885 |
| US-20030100561-A1 | Administering 2-amino-N-(1-(3a-benzyl-2-methyl-3-oxo-2,3,3a, 4,6,7-hexahydro-pyrazolo(4,3-c)pyridine-5-carbonyl)-4-phenyl-butyl) -isobutyramide for treating congestive heart failure, obesity | GIPR, GHSR, GPR119 | LMNA 2213/4885MEN1 1989/4885KMT2A 2757/4885 |
| US-20170197961-A1 | SERINE DERIVATIVES AS GHRELIN RECEPTOR AGONISTS | GHSR, GHRHR, GIPR | LMNA 3989/4885MEN1 1509/4885KMT2A 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.